Trial Profile
Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2016
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Oblimersen (Primary) ; Paclitaxel (Primary)
- Indications Uveal neoplasms
- Focus Therapeutic Use
- 24 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 08 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 08 Nov 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2010-0188).